Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling

Scientific Reports

Volumn 3, Issue , 2014, Pages

  Dai, Xiaofeng ^a   Chen, Ana ^a,b   Bai, Zhonghu ^a  

^a JIANGNAN UNIVERSITY   (China)

^b ANHUI POLYTECHNIC UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; MICRORNA; PROGESTERONE RECEPTOR;

BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PATHOLOGY; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84925383411     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06566     Document Type: Article

References (50)

1. Walker, R. A. Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol 61, 689-696, doi: DOI 10.1136/jcp. 2006.041830 (2008).
2. Dunnwald, L. K., Rossing, M. A. & Li, C. I. Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. Breast Cancer Res 9, R6 (2007).
3. Masood, S. Estrogen and progesterone receptors in cytology: a comprehensive review. Diagn Cytopathol 8, 475-491 (1992).
4. Putti, T. C. et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18, 26-35, doi:10.1038/modpathol.3800255 (2005).
5. Hudis, C. A. & Gianni, L. Triple-negative breast cancer: an unmet medical need. Oncologist 16, 1-11 (2011).
6. Charafe-Jauffret, E. et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25, 2273-2284 (2006).
7. Rakha, E. A. et al. Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes. Clin Cancer Res 15, 2302-2310, doi: Doi 10.1158/1078-0432. Ccr-08-2132 (2009).
8. Guiu, S. et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 23, 2997-3006, doi:10.1093/annonc/mds586 (2012).
9. Blows, F. M. et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10159 Cases from 12 Studies. PLoS Med 7, e1000279 (2010).
10. Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98, 10869-10874, doi: DOI 10.1073/pnas.191367098 (2001).
11. Perou, C. M. et al. Molecular portraits of human breast tumors. Nature 406, 747-752 (2000).
12. Vallejos, C. S. et al. Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database. Clin Breast Cancer 10, 294-300 (2010).
13. Cheang, M. C. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101, 736-750, doi:10.1093/jnci/djp082 (2009).
14. Blenkiron, C. et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8, R214 (2007).
15. Curtis, C. et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486, 346-352, doi:10.1038/nature10983 (2012).
16. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70, doi:10.1038/nature11412 (2012).
17. Sørile, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100, 8418-8423 (2003).
18. Mehra, R. et al. Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis. Cancer Res 65, 11259-11264 (2005).
19. Björnström, L. & Sjöberg, M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actionsontarget genes. Mol Endocrinol 19, 833-842, doi:10.1210/me.2004-0486 (2005).
20. Dweep, H., Sticht, C., Pandey, P. & Gretz, N. miRWalk - database: prediction of possible miRNA binding sites by 'walking' the genes of 3 genomes. J Biomed Inform 44, 839-847 (2011).
21. Chisamore, M. J., Cunningham, M. E., Flores, O., Wilkinson, H. A. & Chen, J. D. Characterization of a Novel Small Molecule Subtype Specific Estrogen-Related Receptor a Antagonist in MCF-7 Breast Cancer Cells. PLoS One 4, e5624 (2009).
22. Lu, D., Kiriyama, Y., Lee, K. Y. & Giguère, V. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. Cancer Res 61, 6755-6761 (2001).
23. Lowery, A. J. et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 11, R27 (2009).
24. Buffa, F. M. et al. MicroRNA associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 71, 5635-5645 (2011).
25. Foekens, J. A. et al. Four miRNAs associated with aggressiveness of lymph nodenegative, estrogen receptor-positive human breast cancer. PNAS 105, 13021-13026 (2008).
26. Teng, D. H. et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57, 5221-5225 (1997).
27. Ling, J. & Kumar, R. Crosstalk between NFkB and glucocorticoid signaling: A potential target of breast cancer therapy. Cancer Lett 322, 119-126, doi: DOI 10.1016/j.canlet.2012.02.033 (2012).
28. Petronzelli, F. et al. Biphasic kinetics of the human DNA repair protein MED1(MBD4), amismatch-specific DNA N-glycosylase. J Biol Chem 275, 32422-32429 (2000).
29. Fedele, C. G. et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. PNAS 107, 22231-22236 (2010).
30. Olayioye, M. A. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 3, 385-389 (2001).
31. Pollok, S., Bauerschmidt, C., Sänger, J., Nasheuer, H. P. & Grosse, F. Human Cdc45 is a proliferation-associated antigen. FEBS J 274, 3669-3684 (2007).
32. Jubb, A. M. et al. Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia. Oncogene 25, 3445-3457 (2006).
33. Kauraniemi, P. & Kallioniemi, A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 13, 39-49 (2006).
34. Dressman, M. A. et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 63, 2194-2199 (2003).
35. Atkinson, J. M. et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer cell 20, 384-399, doi:10.1016/j.ccr.2011.08.013 (2011).
36. Jarzabek, K., Laudanski, P., Dzieciol, J., Dabrowska, M. & Wolczynski, S. Protein kinase C involvement in proliferation and survival of breast cancer cells. Folia Histochem Cytobiol 40, 193-194 (2002).
37. Depowski, P. L. et al. Topoisomerase II alpha expression in breast cancer: Correlation with outcome variables. Modern Pathol 13, 542-547, doi: DOI 10.1038/modpathol.3880094 (2000).
38. Jarvinen, T. A. et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156, 839-847 (2000).
39. Colozza, M. et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16, 1723-1739, doi:10.1093/annonc/mdi352 (2005).
40. Rosenwald, A. et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer cell 3, 185-197 (2003).
41. Alam, H., Sehgal, L., Kundu, S. T., Dalal, S. N. & Vaidya, M. M. Novel function of keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells. Mol Biol Cell 22, 4068-4078 (2011).
42. Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell 144, 646-674, doi: DOI 10.1016/j.cell.2011.02.013 (2011).
43. Syrjakoski, K. et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92, 1529-1531, doi: DOI 10.1093/jnci/92.18.1529 (2000).
44. 2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40, 844-853 (2008).
45. Eerola, H. et al. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res: BCR 7, R93-100 (2005).
46. Tommiska, J. et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 27, 2501-2506, doi: DOI 10.1038/sj.onc.1210885 (2008).
47. Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30, 207-210 (2002).
48. Team, R. D. C. R: A language and environment for statistical computing. (R Foundation for Statistical Computing, 2009).
49. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193, doi: DOI 10.1093/bioinformatics/19.2.185 (2003).
50. Huang Da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37, 1-13, doi:10.1093/nar/gkn923 (2009).